Clinical experience with S-1 or FOLFOX as third-line treatment in patients with metastatic pancreatic cancer who received first-line gemcitabine plus nab-paclitaxel and secondline nanoliposomal-irinotecan+5-FU/leucovorinANNALS OF ONCOLOGYIF65.42024-06-010PRE
JTK-853, a Novel Non-Nucleoside Hepatitis C Virus Polymerase Inhibitor, Demonstrates a High Genetic Barrier to Resistance in vitroJTK-853,一种新型非核苷类丙型肝炎病毒聚合酶抑制剂,在体外表现出较高的耐药基因屏障INTERVIROLOGYIF1.82013-07-052PREAI
Genotypic and Phenotypic Analyses of Hepatitis C Virus from Patients Treated with JTK-853 in a Three-Day MonotherapyANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52013-01-011OAAI
Preclinical Characterization of JTK-853, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA PolymeraseANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52012-08-0116OAAI
Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitorsJOURNAL OF MEDICINAL CHEMISTRYIF6.82006-11-02121PREAI
Antimalarial activity of novel 1,2,5,6-tetraoxacycloalkanes and 1,2,5-trioxacycloalkanesJOURNAL OF MEDICINAL CHEMISTRYIF6.82003-04-0333PREAI
SYNTHESIS OF GENOTOXIC HETEROCYCLIC AMINES TRP-P-1 AND TRP-P-2JOURNAL OF ORGANIC CHEMISTRYIF3.62002-05-0157PREAI
Synthesis and notable antimalarial activity of acyclic peroxides, 1-(alkyldioxy)-1-(methyldioxy)cyclododecanesJOURNAL OF MEDICINAL CHEMISTRYIF6.82002-02-1376PREAI